Linqmed Inc. announced that it has received ¥680 million in round of funding on December 22, 2023. The transaction included the participation from new investors Mizuho Capital Co., Ltd., IWABUCHI YAKUHIN Inc., PeptiDream Inc., Taisho Pharmaceutical Holdings Co., Ltd., Green Core Co., Ltd., Shiratori Pharmaceutical Co., Ltd., DBJ Capital Co., Ltd. and Osaka Kansai Expo Revitalization Fund, a co- fund managed by Bio-Sight Capital Co., Ltd., SBI Chiki Kasseika Shien Co., Ltd. and SBI Regional Business Investment Co., Ltd. The company will issue J-KISS Stock Acquisition Rights. The company has raised ¥930 million funding till the date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,622 JPY | +1.66% | +10.45% | +9.12% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
8,580 JPY | -0.12% | 0.00% | 3.93B | ||
1,622 JPY | +1.66% | +10.45% | 1.34B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.12% | 1.34B | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- 4587 Stock
- News PeptiDream Inc.
- Linqmed Inc. announced that it has received ¥680 million in funding from a group of investors